NANJING WELL PHARMACEUTICAL GROUP CO.,LTD. Nanjing Well Pharmaceutical Group Co.,Ltd. Share Price
Equities
603351
CNE100003JD4
Oil & Gas Refining and Marketing
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.68 CNY | +2.41% |
|
+7.59% | -6.41% |
| Sales 2021 | 1.04B 144M 12.01B | Sales 2022 | 1.11B 153M 12.8B | Capitalization | 2.93B 405M 33.76B |
|---|---|---|---|---|---|
| Net income 2021 | 101M 13.95M 1.16B | Net income 2022 | 95M 13.12M 1.09B | EV / Sales 2021 | 5.01 x |
| Net Debt 2021 | 107M 14.83M 1.24B | Net Debt 2022 | 325M 44.91M 3.75B | EV / Sales 2022 | 2.93 x |
| P/E ratio 2021 |
51.5
x | P/E ratio 2022 |
30.5
x | Employees | 658 |
| Yield 2021 |
0.77% | Yield 2022 |
1.29% | Free-Float | 36.34% |
More Fundamentals
* Assessed data
More news
| 1 day | +2.41% | ||
| 1 week | +7.59% | ||
| Current month | +9.74% | ||
| 1 month | +9.74% | ||
| 3 months | +4.58% | ||
| 6 months | -6.09% | ||
| Current year | -6.41% |
1 week
23.35
25.99
1 month
19.9725.99
Current year
17.6526.96
1 year
17.6529.80
3 years
17.0842.62
5 years
17.0842.62
10 years
17.0842.62
| Managers | Title | Age | Since |
|---|---|---|---|
Ren Rong Wu
CEO | Chief Executive Officer | 61 | 01/00/01 |
Qun Song Tang
DFI | Director of Finance/CFO | 56 | 01/00/01 |
Rong Wen Wu
CHM | Chairman | 58 | 01/00/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ya Mei Guan
BRD | Director/Board Member | 54 | 18/23/18 |
Ren Rong Wu
CEO | Chief Executive Officer | 61 | 01/00/01 |
Zheng Song Gao
CTO | Chief Tech/Sci/R&D Officer | 58 | 01/00/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/24/30 | 24.68 | +2.41% | 1,375,316 |
| 29/24/29 | 24.1 | +1.43% | 700,370 |
| 26/24/26 | 23.76 | -1.53% | 724,500 |
| 25/24/25 | 24.13 | +2.51% | 499,850 |
| 24/24/24 | 23.54 | -1.05% | 459,108 |
End-of-day quote Shanghai S.E., April 30, 2024
More quotes
Nanjing Well Pharmaceutical Group Co Ltd, formerly Nanjing Well Pharmaceutical Co Ltd, is a China-based company principally involved in the research and development, manufacturing and sales of pharmaceutical auxiliary materials and synthetic lubricating base oil products. Its main products include pharmaceutical auxiliary materials, synthetic lubricating base oil and pesticide additives. The Company distributes its products primarily in domestic market.
Calendar
17/05/2024
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| -6.41% | 462M | |
| +13.47% | 238B | |
| +10.65% | 105B | |
| +12.96% | 100B | |
| +23.41% | 63.06B | |
| +8.31% | 59.44B | |
| +21.18% | 50.9B | |
| +23.77% | 36.1B | |
| +33.54% | 27.86B | |
| -10.53% | 21.12B |
- Stock Market
- Equities
- 603351 Stock
